LENDY NUGROHO WISNU MURTI, 051715153009 (2019) PENGARUH TERAPI ORAL LETROZOLE TERHADAP PROFIL LIPID PASIEN KANKER PAYUDARA POST MENOPAUSE DENGAN ER+/PR+ (Penelitian Dilaksanakan di Instalasi Rawat Jalan Poli Hematologi-Onkologi RSU Haji Surabaya). Thesis thesis, Universitas Airlangga.

	Text (ABSTRAK) TFK. 18-19 Mur p ABSTRAK.pdf Download (27kB)
	Text (DAFTAR ISI) TFK. 18-19 Mur p DAFTAR ISI.pdf Download (35kB)
	Text (DAFTAR PUSTAKA) TFK. 18-19 Mur p DAFTAR PUSTAKA.pdf Download (77kB)
	Text (FULLTEXT) TFK. 18-19 Mur p.pdf Restricted to Registered users only until 12 September 2022. Download (1MB) | Request a copy

Abstract

Objective: Breast cancer is malignancy in the breast tissue from the ductal or lobular epithelium. The increased risk of breast cancer is directly related to circulating estrogen levels. One of the management of breast cancer is hormonal therapy given as an adjuvant in stage I-IV breast cancer patients with positive hormonal immunohistochemical parameters (ER + / PR +). Non-steroidal aromatase inhibitor, letrozole, is a hormonal therapy that is often used but increase the risk of cardiovascular disease in postmenopausal women because its inhibition effect of estrogen formation in peripheral tissues. The aim of this study was to analyze the effects of letrozole on lipid profiles in postmenopausal breast cancer patients. Method: This research was prospective observational and approved by the ethics committee of the Surabaya Hajj Hospital. There were 17 sample who met the inclusion criteria. Taking and analyzing blood samples was carried out twice, in the 0th and 1st month in the Clinical Pathology laboratory of the Surabaya Hajj Hospital. Lipid profile were measured using the Cobas 501 Analyser. Result: There were 17 sample who met the inclusion criteria. 52.94% increased in TC levels, 35.29% increased in TG, 17.65% decreased in HDL and 64.71% increased in LDL. The results of the SPSS statistical analysis showed that there were no significant differences in all serum lipid parameters (TC, TG, HDL and LDL) in the 0th and 1st month. Conclusion: Letrozole therapy within 1 month have effect on increasing lipid profile in Total Cholesterol (TC) and Low Density Lipoprotein (LDL), but does not affect the triglyceride (TG) and High Density Lipoprotein (HDL).

Actions (login required)

View Item